-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DDwfNAibtgFCa+fouvRy+TdlyRm7JjoMqxXbTpHLUadyYS9cl6Blzg/T7ddwkDKp lEzN3fcPfurLqReaW+P0sQ== 0000904454-97-000031.txt : 19970222 0000904454-97-000031.hdr.sgml : 19970222 ACCESSION NUMBER: 0000904454-97-000031 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970212 SROS: NONE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELL THERAPEUTICS INC CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-48459 FILM NUMBER: 97527002 BUSINESS ADDRESS: STREET 1: 201 ELLIOTT AVE W STREET 2: STE 400 CITY: SEATTLE STATE: WA ZIP: 98119 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: INTERNATIONAL BIOTECHNOLOGY TRUST PLC CENTRAL INDEX KEY: 0000942257 STANDARD INDUSTRIAL CLASSIFICATION: [] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: FIVE ARROWS HOUSE STREET 2: ST SWITHINS LN CITY: LONDON EC4N 8NR MAIL ADDRESS: STREET 1: FIVE ARROWS HOUSE STREET 2: ST SWITHINS LN CITY: LONDON EC4N 8NR SC 13G 1 Page 1 of 5 Pages SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ SCHEDULE 13G Information Statement pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. ) Cell Therapeutics, Inc. ________________________________________________________________- ___ (Name of Issuer) Common Stock _________________________________________________________________ (Title of Class of Securities) NONE _______________________________________________________________- ___ (CUSIP Number) ________________________ Page 2 of 5 Pages _________________________________________________________________ 1) Name of Reporting Person International S.S. or I.R.S. Identification Biotechnology No. of Above Person Trust plc _________________________________________________________________ 2) Check the Appropriate Box (a) [ ] if a Member of a Group (b) [ ] _________________________________________________________________ 3) SEC Use Only _________________________________________________________________ 4) Citizenship or Place United Kingdom of Organization _________________________________________________________________ Number of Shares 5) Sole Voting 3,731,343 shares Beneficially Power of Common Stock Owned by Each (issuable upon Reporting Person conversion of With: 37,313.433 shares of preferred stock) ________________________________________ 6) Shared Voting Power -0- ________________________________________ 7) Sole Disposi- 3,731,343 shares tive Power of Common Stock (issuable upon conversion of 37,313.433 shares of preferred stock) _______________________________________ 8) Shared Dis- positive Power -0- ________________________________________ 9) Aggregate Amount Beneficially 3,731,343 shares Owned by Each Reporting Person of Common Stock (issuable upon conversion of 37,313.433 shares of preferred stock) _________________________________________________________________ 10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares _________________________________________________________________ 11) Percent of Class Represented by 11.2% Amount in Row (9) _________________________________________________________________ 12) Type of Reporting Person PN Schedule 13G Page 3 of 5 Pages Item 1(a) - Name of Issuer: Cell Therapeutics, Inc. Item 1(b) - Address of Issuer's Principal Executive Offices: 201 Elliot Avenue West, Suite 400 Seattle, WA 98119 Item 2(a) - Name of Person Filing: This statement is being filed by International Biotechnology Trust plc, a corporation organized under the laws of the United Kingdom ("IBT" or the "Reporting Person"). Item 2(b) - Address of Principal Business Office: Five Arrows House St. Swithin's Lane London EC4N 8NR England Item 2(c) - Place of Organization: United Kingdom Item 2(d) - Title of Class of Securities: Common Stock Item 2(e) - CUSIP Number: None. Item 3 - Statements Filed Pursuant to Rules 13d-1(b) or 13d-2(b): Not applicable. Item 4 - Ownership. (a) Amount Beneficially Owned: 3,731,343 shares of Common Stock (issuable upon conversion of 37,313.433 shares of preferred stock) (b) Percent of Class: 11.2% Page 4 of 5 Pages (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 3,731,343 shares of Common Stock (issuable upon conver- sion of 37,313.433 shares of preferred stock) (ii) shared power to vote or to direct the vote: - -0- (iii) sole power to dispose or to direct the disposition of: 3,731,343 shares of Common Stock (issuable upon conversion of 37,313.433 shares of preferred stock) (iv) shared power to dispose or to direct the disposition of: -0- Item 5 - Ownership of Five Percent or Less of a Class: Not applicable. Item 6 - Ownership of More than Five Percent on Behalf of Another Person: Not applicable. Item 7 - Identification and Classification of the Subsid- iary Which Acquired the Security Being Reported on By the Parent Company: Not applicable. Item 8 - Identification and Classification of Members of the Group: Not applicable. Item 9 - Notice of Dissolution of Group: Not applicable. Item 10 - Certification: Not applicable. Page 5 of 5 Pages Signature: After reasonable inquiry and to the best of my knowl- edge and belief, I certify that the information set forth in this state- ment is true, complete and correct. INTERNATIONAL BIOTECHNOLOGY TRUST PLC By /s/ Jeremy L. Curnock Cook Director Dated: January 23, 1997 -----END PRIVACY-ENHANCED MESSAGE-----